N-acetylaspartate (N-acetyl aspartate)

Subscribe to Selected New Research on N-acetylaspartate

767 relevant articles (22 outcomes, 111 trials/studies) found for this Bio-Agent

Also Known As:

N-acetyl aspartate; N-acetyl-L-aspartate; N-acetylaspartate, monopotassium salt; N-acetylaspartic acid

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Amino Acids: 8572

Excitatory Amino Acids: 1084

Aspartic Acid: 1882

N-acetylaspartate: 767

Acidic Amino Acids: 33

Aspartic Acid: 1882

N-acetylaspartate: 767

Dicarboxylic Amino Acids: 20

Aspartic Acid: 1882

N-acetylaspartate: 767

Experts

1.	Weiner, Michael W: 4 articles (02/2008 - 01/2003)
2.	Schuff, Norbert: 4 articles (02/2008 - 01/2003)
3.	Renshaw, Perry F: 3 articles (09/2008 - 01/2007)
4.	Madhavarao, Chikkathur N: 3 articles (08/2008 - 10/2005)
5.	Moffett, John R: 3 articles (08/2008 - 10/2005)
6.	Gonen, O: 3 articles (11/2007 - 11/2006)
7.	Inglese, M: 3 articles (11/2007 - 11/2006)
8.	Grossman, Robert I: 3 articles (09/2003 - 03/2002)
9.	Gonen, Oded: 3 articles (09/2003 - 03/2002)
10.	Schuff, N: 3 articles (08/2003 - 04/2000)

Related Diseases

1.	Neoplasms (Cancer) 03/01/1989 - "As the intracerebral tumor size increased, there was a marked decrease in the N-acetyl aspartate level and an increase in the 1.3 ppm peak" 10/01/2005 - "The purpose of this study was to quantify MR imaging-occult, glial tumor infiltration beyond its radiologic margin through its consequent neuronal cell damage, assessed by the global concentration decline of the neuronal marker N-acetylaspartate (NAA)" 12/01/2007 - "Fractional anisotropy distribution in the tumor correlated positively with N-acetyl aspartate level (P < 0.001), indicating that these parameters reflect (remaining) axonal structure" 09/01/2004 - "A significant correlation between N-acetyl-aspartate level and topometric variables (number of neighbors per nucleus, variables describing distances between tumor cell nuclei) was confirmed for proliferating tumor cell nuclei" 10/01/1994 - "N-Acetyl-aspartate was demonstrated in normal tissues but could not be detected in nonneuroectodermal tumors" Order ALL the reference details at left...
2.	Atrophy 01/01/1996 - "The spectroscopic findings showed a significant reduction of N-acetylaspartate in all parts of the cerebellum, a significant correlation with MRI scores of cerebellar atrophy, and a significant correlation with clinical rating scores of cerebellar disturbance" 06/01/2005 - "Whole-brain N-acetylaspartate values and normalized brain volumes were unrelated in this cohort, thereby suggesting that 1H-MRS and atrophy assessment may provide in vivo complementary information about the actual extent of brain damage in PPMS." 02/22/2005 - "Correlations with clinical scores emphasize the functional relevance of localized atrophy (brain parenchyma fraction) and N-acetyl aspartate levels" 05/01/2004 - "RESULTS: The benign and severely disabled groups had similar brain atrophy metrics and similar decreases of the neuronal marker, N-acetylaspartate, in the normal appearing white matter of the cerebrum on magnetic resonance spectroscopy examination in vivo" 04/01/2004 - "MR surrogate measures for neuroaxonal loss include atrophy (tissue loss in brain and spinal cord), N-acetyl aspartate, and T1 hypointense lesions" Order ALL the reference details at left...
3.	Ischemia 05/01/2003 - "2) In the ischemic group, the level of N-acetyl aspartate (NAA) was decreased within 4 h after ischemia (P<0.05, n=6), and the decline persisted (P<0.01, n=6)" 01/01/2003 - "We investigated changes in regional N-acetyl-aspartate (NAA) levels in the vulnerable CA1 and resistant CA3 areas of the hippocampus after transient forebrain ischemia in gerbils" 01/01/2003 - "Regional N-acetyl-aspartate level and immunohistochemical damage in the hippocampus after transient forebrain ischemia in gerbils." 07/13/2001 - "Four hours after the induction of ischemia, N-acetyl-L-aspartate (NAA) levels in the lateral caudo-putamen and the somatosensory cortex, core ischemic regions, decreased 22 and 40%, respectively" 03/01/1999 - "The contribution of brain temperature changes (calculated from the chemical shift between the water and N-acetylaspartate signals) and tissue deoxygenation to ischemia-induced intracellular ADC changes was minor" Order ALL the reference details at left...
4.	Demyelinating Diseases (Demyelinating Disease) 06/01/2002 - "The N-acetyl aspartate (NAA) peak showed reduction during the early phase of the lesion progression (demyelination) until day 10 and increased thereafter during remyelination" 12/01/1999 - "RESULTS: A significant correlation was found between a reduction in the concentration of N-acetyl aspartate (NAA; an in vivo marker of axonal loss or dysfunction) and a reduction in MT ratio (a probable marker of demyelination) in patients who had entered the secondary progressive stage of the disease" 05/01/2000 - "We aimed to examine the relationship between motor impairment, magnetisation transfer ratio (MTR) (an index of demyelination), and N-acetyl aspartate (NAA) loss (an index of axonal injury) localised to the descending motor pathways in stroke and MS. Twelve patients between 1 and 10 months after first ischaemic stroke causing a motor deficit and 12 patients with stable MS with asymmetric motor deficit were examined" 07/01/1999 - "Recent observations made using magnetic resonance spectroscopy to measure the axonal marker N-acetylaspartate have emphasized the fact that substantial axonal damage occurs in multiple sclerosis, in addition to demyelination" 01/01/1998 - "A number of the acute MR changes are reversible, but chronic persistent abnormalities in a number of MR parameters, such as reduced N-acetyl aspartate, low magnetization transfer ratios, atrophy and T1-hypointensity, suggest the presence of demyelination and/or axonal degeneration in many chronic lesions" Order ALL the reference details at left...
5.	Alzheimer Disease (Alzheimer's Disease) 01/25/2005 - "BACKGROUND: N-acetylaspartate (NAA) in the medial temporal lobe (MTL) and parietal lobe gray matter (GM) is diminished in Alzheimer disease (AD)" 01/01/2005 - "OBJECTIVE: To investigate group differences and correlations and to determine the sensitivity and specificity of different measures of the neuronal marker N-acetylaspartate (NAA) in the medial temporal lobe of Alzheimer's Disease (AD) patients" 01/01/2005 - "A comparative study of the different N-acetylaspartate measures of the medial temporal lobe in Alzheimer's disease." 05/13/2000 - "In patients with Alzheimer's disease, but not in health controls, longitudinal magnetic resonance spectroscopy shows a striking decline in the neuronal marker, N-acetyl aspartate, despite little decline in underlying grey-matter volume." 05/13/2000 - "Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Creatine
2.	Choline (Choline Chloride)
3.	Protons (Proton)
4.	CAV protocol (CHO)
5.	Lactic Acid
6.	Phosphocreatine (Neoton)
7.	Glutamic Acid (Glutamate)
8.	Lipids
9.	Succinic Acid (Succinate)
10.	Glutamate Carboxypeptidase II (N-Acetylaspartylglutamate Peptidase)

Related Therapies and Procedures

1.	Liver Transplantation
2.	Brachytherapy

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 18648 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>